Please login to the form below

Not currently logged in
Email:
Password:

multiple sclerosis

This page shows the latest multiple sclerosis news and features for those working in and with pharma, biotech and healthcare.

Roche’s Ocrevus boasts positive long-term data in MS

Roche’s Ocrevus boasts positive long-term data in MS

Swiss pharma company Roche has released new long-term data that shows 75% of relapsing-remitting multiple sclerosis (RRMS) patients treated with Ocrevus (ocrelizumab) had no evidence of disease activity after ... Following two years of using Ocrevus twice

Latest news

More from news
Approximately 85 fully matching, plus 505 partially matching documents found.

Latest Intelligence

  • The search for treatments for Parkinson’s disease The search for treatments for Parkinson’s disease

    and a decade as senior director of neurodegenerative diseases research at Merck Serono where he served as its leader for in vitro pharmacology in neurology, including in multiple sclerosis, Parkinson’s

  • Cortellis Drugs to Watch in 2020 report Cortellis Drugs to Watch in 2020 report

    of B and T cells outside the lymph nodes, to treat relapsing forms of multiple sclerosis. ... Despite the expectation that it will face intense competition in the crowded multiple sclerosis market, sales of $80m are forecast for this year, rising to

  • 20 for 2020 – Five pharma companies to watch 20 for 2020 – Five pharma companies to watch

    Elsewhere, BMS will need new Celgene prospects like selective JAK2 inhibitor Inrebic (fedratinib) – the first new myelofibrosis therapy in a decade – as well as other new drug candidates like multiple sclerosis ... The following month J&J agreed to a

  • Case study: OptiMiSe for MS nurses Case study: OptiMiSe for MS nurses

    OptiMiSe was launched in 2016 to support Multiple Sclerosis Specialist Nurses (MSSNs) in the provision of individualised care to patients living with MS.

  • Case study: What we're made of Case study: What we're made of

    This could be a side effect of a condition such as stroke, motor neurone disease, multiple sclerosis, learning disability, dementia, Parkinson’s disease, head and neck injury or cancer.

More from intelligence
Approximately 0 fully matching, plus 36 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 25 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 15 fully matching, plus 25 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics